{
    "clinical_study": {
        "@rank": "11458", 
        "arm_group": [
            {
                "arm_group_label": "Acomegaly with Pegvisomant", 
                "description": "Patients receiving pegvisomant monotherapy from own doctor to treat acromegaly."
            }, 
            {
                "arm_group_label": "Acromegaly with somatostatin analog", 
                "description": "Patients receiving somatostatin analog monotherapy from own doctor to treat acromegaly"
            }, 
            {
                "arm_group_label": "Active Acromegaly", 
                "description": "Patients not on drugs for treatment of acromegaly"
            }
        ], 
        "biospec_descr": {
            "textblock": "Plasma and blood serum"
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The investigators hypothesize that treatment of acromegaly will be associated with an\n      improvement in quality of life compared to active acromegaly. At the same time, they will\n      also be studying the effects of different acromegaly treatments on the quality of life."
        }, 
        "brief_title": "Acromegaly Treatment Quality of Life Study", 
        "completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Acromegaly", 
        "condition_browse": {
            "mesh_term": "Acromegaly"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18-75\n\n          -  Active acromegaly or receiving pegvisomant monotherapy or receiving somatostatin\n             analog monotherapy\n\n        Exclusion Criteria:\n\n          -  Untreated thyroid or adrenal insufficiency.  Subjects on replacement therapy must be\n             stable for at least 3 months prior to entry into the study\n\n          -  Initiation or discontinuation of testosterone or estrogen within 3 months of entry\n\n          -  Pregnant and nursing women"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "75 Years", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "There will be 3 groups/cohorts: 1) Patients with active acromegaly (n=30), 2) patients\n        receiving pegvisomant monotherapy to treat acromegaly (n=30), and 3) patients receiving\n        somatostatin analog monotherapy to treat acromegaly (n=60)"
            }
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01732406", 
            "org_study_id": "2012P001556"
        }, 
        "intervention_browse": {
            "mesh_term": "Somatostatin"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "February 4, 2014", 
        "location": {
            "contact": {
                "email": "avgerweck@partners.org", 
                "last_name": "Anu V Gerweck, NP", 
                "phone": "617-724-1837"
            }, 
            "facility": {
                "address": {
                    "city": "Boston", 
                    "country": "United States", 
                    "state": "Massachusetts", 
                    "zip": "02114"
                }, 
                "name": "Massachusetts General Hospital"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "3", 
        "official_title": "Effect of Growth Hormone Receptor Antagonism and Somatostatin Analog Administration on Quality of Life", 
        "overall_contact": {
            "email": "avgerweck@partners.org", 
            "last_name": "Anu v Gerweck, NP", 
            "phone": "617-724-1837"
        }, 
        "overall_official": {
            "affiliation": "Massachusetts General Hospital", 
            "last_name": "Karen Miller, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Quality of Life", 
            "safety_issue": "No", 
            "time_frame": "baseline"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01732406"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Massachusetts General Hospital", 
            "investigator_full_name": "Karen Klahr Miller, MD", 
            "investigator_title": "Assistant Physician in Medicine", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "source": "Massachusetts General Hospital", 
        "sponsors": {
            "collaborator": {
                "agency": "Pfizer", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Massachusetts General Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "February 2014"
    }
}